Phunware (PHUN) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phunware in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHUN shares.
View PHUN analyst ratings or view top-rated stocks.

1 brokers have issued twelve-month target prices for Phunware's shares. Their PHUN share price forecasts range from $2.50 to $5.00. On average, they predict the company's share price to reach $3.75 in the next year. This suggests a possible upside of 545.3% from the stock's current price.
View analysts price targets for PHUN or view top-rated stocks among Wall Street analysts.

Phunware's stock was trading at $0.7733 at the beginning of 2023. Since then, PHUN shares have decreased by 24.9% and is now trading at $0.5811.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our PHUN earnings forecast.

Phunware, Inc. (NASDAQ:PHUN) released its earnings results on Thursday, March, 23rd. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The firm had revenue of $4.77 million for the quarter, compared to analysts' expectations of $5.46 million. Phunware had a negative trailing twelve-month return on equity of 94.83% and a negative net margin of 203.64%.

Invesco Alerian Galaxy Crypto Economy ETF holds 26,300 shares of PHUN stock, representing 0.51% of its portfolio.

65 employees have rated Phunware Chief Executive Officer Alan S. Knitowski on Glassdoor.com. Alan S. Knitowski has an approval rating of 51% among the company's employees. This puts Alan S. Knitowski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Phunware investors own include Biocept (BIOC), NIO (NIO), OPKO Health (OPK), Vaxart (VXRT), Outlook Therapeutics (OTLK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), Acasti Pharma (ACST) and Boeing (BA).

Phunware trades on the NASDAQ under the ticker symbol "PHUN."

Phunware's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.29%), Geode Capital Management LLC (0.91%), Price T Rowe Associates Inc. MD (0.08%), Group One Trading L.P. (0.00%), HAP Trading LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alan S Knitowski, Eric Manlunas, George Syllantavos and Ryan Costello.
View institutional ownership trends.

Shares of PHUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHUN stock can currently be purchased for approximately $0.58.

Phunware (NASDAQ:PHUN) has a market capitalization of $60.82 million and generates $21.79 million in revenue each year. The company earns $-50,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

The company employs 120 workers across the globe.

Phunware's mailing address is 7800 SHOAL CREEK BLVD SUITE 230-S, AUSTIN X1, 78757. The official website for the company is www.phunware.com. The company can be reached via phone at (512) 693-4199 or via email at investorrelations@phunware.com.